Are you Dr. Taber?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 93 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5340 Holy Cross Pkwy
Mishawaka, IN 46545Phone+1 574-237-1328Fax+1 574-237-1348
Summary
- Dr. David Taber, MD is an oncologist in Mishawaka, Indiana. He is currently licensed to practice medicine in Indiana. He is affiliated with Saint Joseph Health System, Memorial Hospital of South Bend, and Elkhart General Hospital.
Education & Training
- Cook County Health and Hospitals SystemFellowship, Hematology and Medical Oncology, 1983 - 1985
- Cook County Health and Hospitals SystemResidency, Internal Medicine, 1980 - 1983
- University of Illinois College of MedicineClass of 1980
Certifications & Licensure
- IN State Medical License 1989 - 2021
Clinical Trials
- Decitabine in Treating Patients With Myelofibrosis Start of enrollment: 2004 Sep 29
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
- Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors Start of enrollment: 2009 Mar 16
- Join now to see all
Publications & Presentations
PubMed
- 168 citationsMulticenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant MesotheliomaHedy L. Kindler, Theodore Karrison, David R. Gandara, Charles Lu, Lee M. Krug
Journal of Clinical Oncology. 2012-07-10 - 39 citationsDasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II ConsortiumManish R. Sharma, Kristen Wroblewski, Blase N. Polite, James A. Knost, James A. Wallace
Investigational New Drugs. 2012-06-01 - 168 citationsFlavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium StudyWalter M. Stadler, Nicholas J. Vogelzang, Robert J Amato, Jeffery Sosman, David A. Taber
Journal of Clinical Oncology. 2000-01-01